drugset
drugset / Trial / NCT07318389

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

NCT07318389 ↗

Phase 0 Not yet recruiting 100 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Timeline

Start
2026-06-10
Primary completion
2027-11-14
Completion
2029-11-14

Drugs

EvaluationDrugModalityDoseRoute
Background Adagrasib Small molecule — Oral
Background Bevacizumab Monoclonal antibody — Intravenous
Background Cetuximab Monoclonal antibody — Intravenous
Background Encorafenib Small molecule — Oral
Background Panitumumab Monoclonal antibody — Intravenous
Background Sotorasib Small molecule — Oral
Background Tipiracil Small molecule — Oral
Background Trastuzumab deruxtecan Monoclonal antibody — Intravenous
Background Trifluridine Small molecule — Oral
Background Tucatinib Small molecule — Oral

Indications

colorectal cancer